ENCEFA is a biotechnology company developing innovative therapeutic drugs for the treatment of central nervous system diseases. ENCEFA develops a compound targeting Parkinson's disease. This molecule, which acts through a novel mechanism of action in the treatment of neurodegenerative diseases, is the culmination of several years of research at the Brain and Spine Institute (ICM, Paris). The hallmark of Encefa is to identify and develop its compounds using qualitative cellular models with high predictive power. Thus, by concentrating its efforts on the preclinical stage, ENCEFA de-risks the clinical validation of its molecules.